$5 million in funding available for Tennessee senior centers: What to know
The Tennessee General Assembly has set aside $5 million in one-time funding for senior centers throughout the state. This money is meant to help give older adults access to resources, activities and social connections. It can be spent on goals including:
Capital Projects, such as building improvements and equipment
Marketing
Programming and activities
Routine operating expenses other than staff salaries
Applications are due by 4 p.m. central time on August 8, and centers have to spend the funding by March 31, 2027. Centers can apply for funding between $10,000 and $50,000.
Morristown hosts the Tennessee State Disc Golf Championships
Individuals and long-term care/assisted living facilities are not included. The state gave the following qualifications for centers:
A single-purpose agency with programs and activities designed and operated only for the benefit of adults aged 60 and over; or
A multi-purpose agency with a broad spectrum of services, which shall include provisions of health, social, nutritional, and educational services, and the provision of facilities for recreational activities for adults aged 60 and over; and,
An organization with established programming that provides a minimum of 16 hours a month of activities or services specifically targeted for adults 60 and over.
READ: More top stories on WATE.com
'DDA is committed to ensuring senior centers in both rural and urban communities across the state are vibrant and thriving,' said DDA Commissioner Brad Turner. 'We hope this funding can help enhance the offerings, improve equipment, modernize buildings, and ensure that our senior centers continue to be spaces where older adults can access resources, connect with their peers, and enjoy a wide range of activities.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
23-07-2025
- The Hill
2 children in Tennessee recovering from rare La Crosse virus spread by mosquitoes
KNOX COUNTY, Tenn. (WATE / WJW) — Two children in Tennessee are now recovering at home after being hospitalized for La Crosse virus, a rare mosquito-borne virus that can, in severe cases, lead to inflammation of the brain. The Knox County Health Department said the two children were hospitalized earlier this month. They mark the first cases of the virus this year in the county, according to health officials. Meanwhile in Ohio, a 66-year-old man was recently confirmed to have contracted La Crosse virus, Nexstar's WJW reports. What is La Crosse virus? La Crosse virus is a mosquito-borne infection. Most people who get it don't have symptoms, but those who do can have a fever, a headache, nausea, and vomiting, Knox County health officials said. In rare cases, it can become severe and lead to inflammation of the brain, or encephalitis. 'Severe disease occurs most often in children under 16 years old,' said a KCHD spokesperson. 'Most severe cases require hospitalization but will recover with supportive care. However, up to 15 percent of cases can have major neurologic complications.' According to the Centers for Disease Control and Prevention, between 30 and 90 La Crosse cases are reported annually. But this number is thought to be a 'substantial under-diagnosis' due to the 'under-reporting of less severe cases.' Cases are primarily found during the late spring through early fall while mosquitoes are most active. How is La Crosse virus spread? It comes from the bite of an infected Aedes triseriatus, or eastern treehole mosquito. The Aedes mosquitoes primarily bite people in wooded areas during dawn and dusk. 'They are a little bit more of a shy mosquito, they don't aggressively come out and bite people,' Caroline Terakedis, director of environmental health services for the Tuscarawas County Health Department, told WJW. 'It's difficult to treat standing water for them because they prefer to breed in small tiny areas like tree holes, but they really like scrap tires.' 5 million above-ground pools recalled after deaths reported in 6 states Humans do not spread the virus, the CDC says. Symptoms can occur within five to 15 days of a bite. Where have cases been reported? CDC data shows that between 2003 and 2024, more than 1,500 cases of La Crosse virus were reported, with 15 confirmed deaths over the same time period. Nearly two dozen states saw at least one case of La Crosse virus during that time. North Carolina and Ohio each saw over 300 cases, while Tennessee and West Virginia had over 200 each. Other states that recorded at least one case include Alabama, Florida, Georgia, Iowa, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maryland, Michigan, Minnesota, Missouri, Mississippi, Rhode Island, South Carolina, Texas, Virginia, and Wisconsin. 'Quiet cracking' is the newest term for a workplace problem — and it's 'pretty pervasive,' expert says The vast majority of human cases reported to the CDC were among those under the age of 18. How to avoid getting La Crosse virus Similar to advice for preventing West Nile virus, health experts recommend using insect repellants (such as DEET, Picaridin, IR3535 and oil of lemon eucalyptus), treating your clothes with repellents like permethrin, wearing long-sleeved shirts and pants while near wooded areas, and covering strollers with mosquito netting. Knox County health officials also recommended reducing standing water on your property to control the mosquito population. This includes turning over items that hold water, like flowerpot saucers, once a week. Health officials have advised parents and guardians to seek emergency care if they see neurological issues in their children. This would include seizures, mental changes, and drowsiness or trouble staying awake. The Tuscarawas County Health Department says there is no vaccine against the virus, and there are no medications to specifically treat La Crosse encephalitis.
Yahoo
23-07-2025
- Yahoo
Archax to Acquire Deutsche Digital Assets, Expanding Crypto ETP Reach in Europe
UK-based digital asset exchange Archax is set to acquire Deutsche Digital Assets (DDA), a regulated crypto asset manager in Germany, in a move that strengthens its footprint in Europe's two largest financial markets. DDA manages around $70 million in assets and specializes in crypto exchange-traded products (ETPs) distributed through a network of European banks and asset managers. The deal gives Archax new licenses under Germany's BaFin, including permissions for portfolio management and investment advisory—key capabilities for serving institutional clients in the EU. This acquisition builds on Archax's 2023 purchase of Spanish broker KSCM. With the DDA deal, Archax now holds regulatory approvals in the UK, Germany, France and Spain, allowing it to operate across much of Europe's fragmented digital asset landscape. While the UK only recently opened the door to crypto ETPs for professional investors, Germany has had a head start. Archax now gains access to a market already accustomed to these products, along with the regulatory permissions to issue and distribute them. The timing may prove important as market demand for tokenized assets and regulated digital instruments grows amid geopolitical uncertainty. Archax also offers tokenized real-world assets—such as private equity or real estate—alongside its crypto offerings, positioning itself as a bridge between traditional finance and blockchain infrastructure. Archax CEO Graham Rodford said the deal positions his firm as one of the most comprehensively licensed digital asset firms in Europe. DDA managing partner Maximilian Lautenschläger described the move as a natural fit that opens new market channels on both sides of the channel. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
15-07-2025
- Business Wire
Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a pioneering artificial intelligence (AI) company transforming oncology drug discovery and development, today announced the launch of an innovative AI-powered module within its proprietary RADR ® platform, designed to predict the activity and efficacy of combination regimens involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis) in clinical cancer treatment. With the global market for combination cancer therapies projected to exceed $50 billion by 2030, growing at a CAGR of 8.5%, this module represents a significant advancement in precision oncology, enabling faster, more cost-effective development of tailored therapeutic regimens. Leveraging this AI-driven framework, Lantern Pharma has successfully architected and achieved FDA clearance for a Phase 1B/2 clinical trial in triple-negative breast cancer (TNBC), focusing on a novel DDA-DDRi combination regimen with promising preclinical efficacy. This AI-powered module is a transformative step in our mission to deliver personalized cancer treatments. By leveraging our RADR® platform to analyze complex multi-omics and clinical trial data, we identified optimal DDA-DDRi combinations that guided... Share In a peer-reviewed study published in Frontiers in Oncology, Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review, Lantern Pharma researchers systematically analyzed 221 DDA-DDRi combination-arm clinical trials, involving 22 DDAs and 46 DDRis, to develop this module. The study categorized DDAs into eight subclasses (e.g., alkylating agents, interstrand cross-linkers) and DDRis into 14 subclasses (e.g., PARP, ATR, WEE1 inhibitors). From these, 89 trials with interpretable outcomes were scored for clinical effectiveness, safety, and biomarker-driven responses, providing a robust dataset to train the AI module. 1 Transforming Cancer Combination Therapy Development The new AI module represents a paradigm shift in precision oncology, leveraging machine learning to predict which drug combinations will be most effective for specific patient populations while minimizing toxicity risks. This data-driven approach has already demonstrated its value by successfully guiding the design of Lantern's FDA-cleared Phase 1B/2 clinical trial combining LP-184 with olaparib in triple-negative breast cancer (TNBC). "This AI-powered module is a transformative step in our mission to deliver personalized cancer treatments," said Panna Sharma, CEO & President of Lantern Pharma. "By leveraging our RADR ® platform to analyze complex multi-omics and clinical trial data, we identified optimal DDA-DDRi combinations that guided the development of our TNBC trial. We believe this approach could reduce combination therapy development timelines and costs by one-third compared to traditional methods." The module integrates genomic, transcriptomic, and clinical data to predict synergistic drug interactions, optimize therapeutic outcomes, and identify biomarker-defined patient subpopulations likely to respond to specific combinations. This data-driven approach directly informed the design of Lantern's FDA-cleared Phase 1B/2 trial in TNBC for LP-184 and olaparib, with potential to improve response rates and reduce toxicity. Key insights from the study powering the AI module include: Non-PARP Inhibitor Promise: Non-PARP DDRi combinations, particularly WEE1 inhibitors like adavosertib with platinum agents, showed an 80% positive outcome rate in interstrand cross-linker trials, with strong efficacy in TP53-mutated cancers, directly informing future trial design. Biomarker-Driven Success: Biomarkers such as TP53 mutations and HRD signatures were critical predictors of response, enabling patient stratification to maximize efficacy. Toxicity Mitigation: The use of novel formulations like liposomal doxorubicin in combination regimens reduced cardiotoxicity, providing a safer backbone for combination strategies. Emerging Trends: The analysis emphasizes the patterns in treatment effectiveness, safety, and emerging trends across various cancer types and discusses the potential of biomarkers to guide treatment selection and improve patient outcomes. The module's multi-agentic framework integrates specialized AI agents for data aggregation, drug classification, predictive modeling, biomarker identification, and optimization, creating a dynamic system that is planned to evolve along with new data. The system's continuous learning capability ensures adaptability, enabling Lantern to refine regimens and accelerate future trials across diverse cancer indications. The company is exploring licensing and commercialization opportunities to expand the application of this technology, further revolutionizing combination therapy development. About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI-driven biotechnology company focused on accelerating and optimizing the discovery, development, and commercialization of cancer therapies. Its RADR ® platform leverages artificial intelligence and machine learning to uncover novel therapeutic opportunities, accelerate drug development, and improve patient outcomes. Please find more information at: Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR ® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR ® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR ® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 27, 2025. You may access our Annual Report on Form 10-K for the year ended December 31, 2024 under the investor SEC filings tab of our website at or on the SEC's website at Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations. 1 Fontenot R, Biyani N, Bhatia K, Ewesuedo R, Chamberlain M and Sharma P (2025) Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review. Front. Oncol. 15:1577468. doi: 10.3389/fonc.2025.1577468
